Effects of albiglutide on myocardial infarction and ischemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial.

Konstantin A KrychtiukGuillaume Marquis-GravelShannon MurphyKaren P AlexanderKaren ChiswellJennifer B GreenLawrence Alan LeiterRenato LopesStefano Del PratoWilliam Schuyler JonesJohn J V McMurrayAdrian F HernandezChristopher B Granger

Published in: European heart journal. Cardiovascular pharmacotherapy (2024)

Treatment with the GLP-1 receptor agonist albiglutide resulted in a 25% relative risk reduction in myocardial infarction that was consistent for type of infarction and presence or absence of ST elevation. Our findings add novel information about the effects of GLP-1 receptor agonists on ischemic events in patients with type 2 diabetes.

Keyphrases

cardiovascular disease
heart failure
left ventricular
clinical trial
type diabetes
study protocol
healthcare
phase iii
metabolic syndrome
coronary artery disease
ischemia reperfusion injury
atrial fibrillation
adipose tissue
cardiovascular risk factors
cardiovascular events
glycemic control
blood brain barrier